(ALT) Altimmune, Inc. BCG Matrix Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(ALT) Altimmune, Inc. Complete Analysis Pack
Actionable Strategy Starts Here
This Altimmune, Inc. BCG Matrix helps you quickly see how the company’s products or business units may fit into the Stars, Cash Cows, Question Marks, and Dogs framework. This page already shows a real preview of the actual analysis, so you can review the format and content before buying. Purchase the full version to get the complete ready-to-use report.
Stars
0 approved products
Altimmune had 0 approved products by end-2025, so it had no marketed drug with commercial share in a growing market. That means it had no true Star in BCG terms. In 2025, the company still depended on pipeline assets like pemvidutide, not product sales.
0 commercial market-share leaders
In fiscal 2025, Altimmune had no approved obesity, liver disease, or hepatitis B product, so it had 0 commercial market-share leaders. The portfolio stayed pre-revenue and trial-led, with pemvidutide in Phase 2 studies and HepTcell still early-stage. Without sales or market share, no high-share strength had been built yet.
No revenue-generating brand
Altimmune, Inc. had no product sales, so its "Star" was not a revenue engine that could fund growth; in Q1 2025 it still reported $0 revenue and a net loss, with cash used to support R&D. Without a launched brand, it could not recycle Star cash into expansion, so it stayed reliant on capital markets and execution of its pemvidutide pipeline. That makes growth depend on clinical milestones, not operating cash flow.
No approved obesity franchise
Pemvidutide remained investigational in 2025, so Altimmune, Inc. had 0 obesity market share and no approved obesity franchise. The obesity drug market was still huge, with global sales near $25 billion and double-digit growth, but Altimmune had not turned that demand into a commercial asset. That is classic Question Mark territory, not a Star.
No approved obesity product in 2025.
Pemvidutide was still in clinical testing.
0 market share in obesity.
Large market, weak monetization.
No approved liver-disease franchise
Altimmune had no approved therapy for MASH or any other liver disease, so its liver pipeline had no commercial product to anchor a Star position. The addressable MASH market was still large, with more than 100 million adults affected globally, but without an approved launch, Altimmune’s liver unit stayed a development-stage bet, not a market leader.
No approved liver-disease product
Large MASH market, no sales base
Pipeline-only asset, not a Star
Altimmune Remains a Pipeline Story, Not a Market Leader
Altimmune, Inc. had no Star in 2025 or 2026 because it had 0 approved products and 0 commercial market share. Pemvidutide was still in Phase 2, so growth depended on trial data, not sales. In obesity and MASH, Altimmune, Inc. stayed a pipeline story, not a market leader.
| Metric | 2025 |
|---|---|
| Approved products | 0 |
| Revenue | $0 |
| Obesity share | 0% |
| Pemvidutide stage | Phase 2 |
What is included in the product
Detailed Word Document
Altimmune’s BCG Matrix maps its pipeline by growth and share, highlighting where to invest, hold, or divest.
Editable Excel File
One-page Altimmune, Inc. BCG Matrix that quickly spots each asset’s quadrant and eases portfolio decisions
Reference Sources
Provides a credible source trail for Altimmune, Inc. that strengthens confidence, speeds due diligence, and supports better investment decisions.
Cash Cows
0 mature commercial franchises
By end-FY2025, Altimmune, Inc. had no legacy product with stable sales, and it still had no approved commercial franchise to generate repeat cash flow. Its FY2025 revenue was not driven by product sales, so there was no mature, low-growth, high-share business to classify as a Cash Cow. In BCG terms, there was nothing to milk: the portfolio was still development-stage, not cash-generating.
0 product revenue streams
Altimmune, Inc. had 0 product revenue in FY2025 and stayed clinical-stage, so it had no recurring sales stream to classify as a Cash Cow. Operating cash came from financing and investments, not product monetization; Altimmune reported cash, cash equivalents, and marketable securities of about $170 million at year-end 2025. With no marketed drug, cash flow was not predictable.
0 royalty base
Altimmune had no meaningful royalty-bearing commercial asset, so its Cash Cows base was 0. Royalty income is usually a classic Cash Cow because it brings in cash with little extra growth spend, but Altimmune reported $0 royalty revenue in its latest filings. That means there was no mature, self-funding stream to offset R&D burn.
0 dividend-supporting asset
Altimmune had no established business unit generating excess cash, so it did not have a Cash Cow to fund dividends. In its latest reported year, revenue was still minimal and the company continued to post operating losses, which is the opposite of a mature, cash-rich franchise.
- No dividend-supporting asset
- No mature, profitable cash engine
- Still in investment mode, not harvest mode
0 low-growth dominant brand
Altimmune, Inc. had 0 Cash Cows because it had no marketed product and no low-growth, high-share franchise. The company still depended on pemvidutide and other pipeline assets, so value was tied to proving efficacy and safety, not harvesting mature cash flow. In its latest reported year, product revenue was $0, so there was no cash engine to fund growth.
- 0 marketed leader
- Product revenue: $0
- Pipeline still in proof stage
- No mature cash cow base
Altimmune Had No Cash Cow in FY2025
Altimmune, Inc. had no Cash Cow in FY2025 because it had no marketed product, no product revenue, and no royalty stream. Revenue was $0, so there was no mature franchise to fund growth or offset R&D burn. Year-end cash, cash equivalents, and marketable securities were about $170 million, but that was funding, not operating cash flow.
| Metric | FY2025 |
|---|---|
| Product revenue | $0 |
| Royalty revenue | $0 |
| Cash, cash equivalents, marketable securities | ~$170 million |
Full Version Awaits
Altimmune, Inc. Reference Sources
The Altimmune, Inc. BCG Matrix preview you see here is the exact same document you’ll receive after purchase. No watered-down sample content—just the full, ready-to-use report in its final format. Once purchased, the complete file is instantly yours for download, editing, printing, or presentation. What you preview is what you get.
Dogs
AdCOVID discontinued in 2021
Altimmune discontinued AdCOVID in 2021 after early clinical testing showed no clear path forward, and the program has produced no commercial revenue since. In BCG terms, that makes it a Dog: low market fit, no recovery route, and it consumed R&D time and cash without becoming an asset. Altimmune’s FY2025 filing still shows no value recovery from AdCOVID, reinforcing the write-off profile.
Legacy vaccine-only portfolio
Altimmune began as Vaxin Inc., and its legacy vaccine-only assets never became meaningful revenue drivers. In FY2024, the Company still had no marketed vaccine product and reported only research-stage value from that old portfolio, while it pushed capital into its metabolic pipeline. That makes the legacy vaccine set a clear Dogs asset in the BCG Matrix: low share, low growth, and limited commercial payoff.
0 approved influenza products
Altimmune had 0 approved influenza products by end-2025, so it had no marketed flu vaccine to defend, price, or harvest cash from. With no mature influenza brand, the segment generated no meaningful revenue base or operating leverage. In BCG terms, this left the category with no strong business unit and no real cash-cow profile.
0 approved COVID-19 products
Altimmune, Inc. had 0 approved COVID-19 products, so the program never reached sales, distribution, or market share. Its intranasal COVID-19 vaccine candidate, AdCOVID, was dropped in 2021 after poor immunogenicity data, with no FDA approval or launch. That makes the asset a clear Dog in BCG terms: low return, no market presence, and exit-level value.
- 0 approved COVID-19 products
- AdCOVID was discontinued in 2021
- No approval, sales, or market entry
No commercialized legacy brand
Altimmune, Inc. had no commercialized legacy brand to fund the business in FY2025, so its old identity did not leave a cash-generating product behind. In BCG terms, those discontinued programs were Dogs: low share, low growth, and no fit with the current model. The company’s 2025 revenue was still tied to pipeline activity, not an old brand.
- Discontinued legacy programs added no revenue.
- No old-brand cash engine remained in FY2025.
- Current value sits in the pipeline, not legacy assets.
Altimmune’s Legacy Vaccine Dogs Are Officially Off the Board
Altimmune’s Dogs are its discontinued legacy vaccine assets, led by AdCOVID, which was dropped in 2021 after weak early data and generated no commercial sales through FY2025. With 0 approved COVID-19 products and 0 approved influenza products by end-2025, these programs had low share, no revenue base, and no recovery path.
| Dog asset | FY2025 status | BCG signal |
|---|---|---|
| AdCOVID | Discontinued, no sales | Low share, low growth |
| Legacy vaccine set | No marketed product | No cash engine |
Question Marks
Pemvidutide obesity
Pemvidutide was Altimmune, Inc.'s main obesity candidate in 2025 and stayed investigational, so it had no sales or market share yet. That fits a Question Mark: the obesity market is huge, with over 1 billion people living with obesity worldwide, but the drug still faced clinical, regulatory, and commercial risk. If Phase 2b data convert into approval, the upside could be large; if not, value stays limited.
Pemvidutide MASH/NASH
Pemvidutide is Altimmune, Inc.'s GLP-1/glucagon dual agonist for MASH/NASH, a market with rising demand but still high clinical risk. In the phase 2 IMPACT study, it cut liver fat by 81% at 24 weeks and drove about 10.3% mean weight loss, but it still needs stronger proof, FDA path clarity, and launch execution. That makes it a BCG Question Mark today; it can become a Star only if late-stage data and approval succeed.
HepTcell chronic hepatitis B
HepTcell for chronic hepatitis B stayed a Question Mark because it was only in Phase 2 and Altimmune, Inc. had no commercial HBV presence. HBV still affects about 254 million people worldwide, with WHO estimating about 1.2 million new infections each year, so the unmet need is large. But without approved revenue or a sales base in this market, the program had upside potential with high execution risk.
GLP-1 glucagon dual agonist platform
Altimmune, Inc.'s GLP-1/glucagon dual agonist platform is a Question Mark: pemvidutide is designed to drive weight loss and improve metabolism in one shot, but it still needs late-stage proof. In the Phase 2 IMPACT study, pemvidutide cut body weight by up to 15.6% at 48 weeks and lowered liver fat by 86.0%, but the company still posted a net loss of $74.3 million in 2025, so execution risk remains high.
If Phase 3 data confirm durable efficacy and safety, the platform could separate itself from single-agonist rivals. Until then, it is a high-potential but unproven bet in Altimmune, Inc.'s BCG mix.
- Strong early efficacy, not yet validated
- Dual action may support differentiation
- 2025 losses show funding pressure
Clinical-stage pipeline
Altimmune's value at end-2025 still rested on readouts from pemvidutide and the rest of its clinical pipeline, not on product sales, because the Company had no commercial revenue and remained in R&D mode. That makes the pipeline a classic Question Mark in BCG terms: high cash burn, high upside, and real failure risk.
- End-2025 value depended on trial data
- No product sales, only pipeline spending
- High upside, but binary clinical risk
That is why the Clinical-stage pipeline sits in Question Marks.
Pemvidutide’s Big Promise, Big Risk in Altimmune’s 2025 Story
Pemvidutide kept Altimmune, Inc. in Question Marks in 2025: it had no sales, but Phase 2 data were strong, with up to 15.6% weight loss at 48 weeks and 86.0% liver-fat reduction. The obesity and MASH markets are large, but approval, safety, and launch risk stay high. Altimmune, Inc. also posted a net loss of $74.3 million in 2025.
| Metric | 2025 |
|---|---|
| Net loss | $74.3 million |
| Pemvidutide sales | $0 |
| Phase 2 weight loss | 15.6% |
| Liver-fat reduction | 86.0% |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.